CXCL-14与冠心病合并糖尿病的研究进展

摘要/Abstract

关键词: CXCL-14, 炎症因子, 冠心病, 2型糖尿病

中图分类号:

R541.4

翟胜男, 李博, 张强, 高宇, 金凤表, 侯瑞田. CXCL-14与冠心病合并糖尿病的研究进展[J]. 承德医学院学报, 2025, 42(6): 510-514.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: http://tougao.cdmc.edu.cn:8088/CN/

http://tougao.cdmc.edu.cn:8088/CN/Y2025/V42/I6/510

[1] Goodarzi MO, Rotter JI.Genetics insights in the relationship between type 2 diabetes and coronary heart disease[J]. Circ Res, 2020, 126(11): 1526-1548.
[2] Zarkasi KA, Murad NAA, Ahmad N, et al.Coronary heart disease in type 2 diabetes mellitus: genetic factors and their mechanisms, gene-gene, and gene-environment interactions in the asian populations[J]. Int J Environ Res Public Health, 2022, 19(2): 647.
[3] Lu T, Forgetta V, Yu OHY, et al.Polygenic risk for coronary heart disease acts through atherosclerosis in type 2 diabetes[J]. Cardiovasc Diabetol, 2020, 19(1): 12.
[4] Mcfadyen JD, Peter K.Platelet CXCL14: Introducing a new player and potential therapeutic target in thromboinflammation[J]. Cardiovasc Res, 2021, 117(3): 645-647.
[5] Lu X, Wang Z, Ye D, et al.The role of CXC chemokines in cardiovascular diseases[J]. Front Pharmacol, 2022, 12: 765768.
[6] Schories C, Martus P, Guan T, et al.Platelet versus plasma CXCL14, coronary artery disease, and clinical outcomes[J]. Res Pract Thromb Haemost, 2023, 7(4): 100165.
[7] Chatterjee M, Geisler T.Inflammatory contribution of platelets revisited: New players in the arena of inflammation[J]. Semin Thromb Hemost, 2016, 42(3): 205-214.
[8] Chang TM, Chiang YC, Lee CW, et al.CXCL14 promotes metastasis of non-small cell lung cancer through ACKR2-depended signaling pathway[J]. Int J Biol Sci, 2023, 19(5): 1455-1470.
[9] Kouzeli A, Collins PJ, Metzemaekers M, et al.CXCL14 preferentially synergizes with homeostatic chemokine receptor systems[J]. Front Immunol, 2020, 11: 561404.
[10] Hamwi GA, Namasivayam V, Büschbell B, et al.Proinflammatory chemokine CXCL14 activates MAS-related G protein-coupled receptor MRGPRX2 and its putative mouse ortholog MRGPRB2[J]. Commun Biol, 2024, 7(1): 52.
[11] Rajagopalan L, Rajarathnam K.Structural Basis of Chemokine Receptor Function-A Model for Binding Affinity and Ligand Selectivity[J]. Biosci Rep, 2006, 26(5): 325-339.
[12] Peterson FC, Thorpe JA, Harder AG, et al.Structural determinants involved in the regulation of CXCL14/BRAK expression by the 26 S proteasome[J]. J Mol Biol, 2006, 363(4): 813-822.
[13] Lu J, Chatterjee M, Schmid H, et al.CXCL14 as an emerging immune and inflammatory modulator[J]. J Inflamm (Lond), 2016, 13(1): 1.
[14] Witte A, Rohlfing AK, Dannenmann B, et al.The chemokine CXCL14 mediates platelet function and migration via direct interaction with CXCR4[J]. Cardiovasc Res, 2021, 117(3): 903-917.
[15] Mcfadyen JD, Peter K.Platelet CXCL14: Introducing a new player and potential therapeutic target in thromboinflammation[J]. Cardiovasc Res, 2021, 117(3): 645-647.
[16] Björkegren JLM, Lusis AJ.Atherosclerosis: Recent developments[J]. Cell, 2022, 185(10): 1630-1645.
[17] Jebari-Benslaiman S, Galicia-García U, Larrea-Sebal A, et al.Pathophysiology of atherosclerosis[J]. Int J Mol Sci, 2022, 23(6): 3346.
[18] Kloc M, Kubiak JZ, Ghobrial RM.Macrophage-, dendritic-, smooth muscle-, endothelium-, and stem cells-derived foam cells in atherosclerosis[J]. Int J Mol Sci, 2022, 23(22): 14154.
[19] Tong W, Duan Y, Yang R, et al.Foam cell-derived CXCL14 muti-functionally promotes atherogenesis and is a potent therapeutic target in atherosclerosis[J]. J Cardiovasc Transl Res, 2020, 13(2): 215-224.
[20] Fateh-Moghadam S, Li Z, Ersel S, et al.Platelet degranulation is associated with progression of intima-media thickness of the common carotid artery in patients with diabetes mellitus type 2[J]. Arterioscler Thromb Vasc Biol, 2005, 25(6): 1299-1303.
[21] Hidenori K, Takaaki M, Shinya F, et al.Platelet P-selectin expression is associated with atherosclerotic wall thickness in carotid artery in humans[J]. Circulation, 2003, 108(5): 524-529.
[22] Coppinger JA, Cagney G, Toomey S, et al.Characterization of the proteins released from activated platelets leads to localization of novel platelet proteins in human atherosclerotic lesions[J]. Blood, 2004, 103(6): 2096-2104.
[23] Rath D, Chatterjee M, Borst O, et al.Expression of stromal cell-derived factor-1 receptors CXCR4 and CXCR7 on circulating platelets of patients with acute coronary syndrome and association with left ventricular functional recovery[J]. Eur Heart J, 2014, 35(6): 386-394.
[24] Chatterjee M, Seizer P, Borst O, et al.SDF-1α induces differential trafficking of CXCR4-CXCR7 involving cyclophilin A, CXCR7 ubiquitination and promotes platelet survival[J]. FASEB J, 2014, 28(7): 2864-2878.
[25] Nording H, Baron L, Langer HF.Platelets as therapeutic targets to prevent atherosclerosis[J]. Atherosclerosis, 2020, 307: 97-108.
[26] Wondmkun YT.Obesity, insulin resistance, and type 2 diabetes: Associations and therapeutic implications[J]. Diabetes Metab Syndr Obes, 2020, 13: 3611-3616.
[27] Zatterale F, Longo M, Naderi J, et al.Chronic adipose tissue inflammation linking obesity to insulin resistance and type 2 diabetes[J]. Front Physiol, 2020, 10: 1607.
[28] Cereijo R, Gavaldà-Navarro A, Cairó M, et al. CXCL14, a brown adipokine that mediates brown-fat-to-macrophage communication in thermogenic adaptation[J]. Cell Metab, 2018, 28(5): 750-763.e6.
[29] Garcia-Beltran C, Cereijo R, Plou C, et al.Posterior cervical brown fat and CXCL14 levels in the first year of life: Sex differences and association with adiposity[J]. J Clin Endocrinol Metab, 2022, 107(3): e1148-e1158.
[30] Chan PC, Hsieh PS.The chemokine systems at the crossroads of inflammation and energy metabolism in the development of obesity[J]. Int J Mol Sci, 2021, 22(24): 13528.
[31] Matsushita Y, Hasegawa Y, Takebe N, et al.Serum C-X-C motif chemokine ligand 14 levels are associated with serum C-peptide and fatty liver index in type 2 diabetes mellitus patients[J]. J Diabetes Investig, 2021, 12(6): 1042-1049.
[32] He W, Wang H, Yang G, et al.The Role of Chemokines in Obesity and Exercise-Induced Weight Loss[J]. Biomolecules, 2024, 14(9): 1121.
[33] Ma CX, Ma XN, Guan CH, et al.Cardiovascular disease in type 2 diabetes mellitus: Progress toward personalized management[J]. Cardiovasc Diabetol, 2022, 21(1): 74.
[34] Tanegashima K, Okamoto S, Nakayama Y, et al.CXCL14 deficiency in mice attenuatesobesity and inhibits feeding behavior in a novel environment[J]. PLoS One, 2017, 5(4): e10321.
[35] Grayson BL, Wang L, Aune TM.Peripheral blood gene expression profiles in metabolic syndrome, coronary artery disease and type 2 diabetes[J]. Genes Immun, 2011, 12(5): 341-351.
[36] Mcfadyen JD, Peter K.Platelet CXCL14: Introducing a new player and potential therapeutic target in thromboinflammation[J]. Cardiovasc Res, 2021, 117(3): 645-647.

CXCL-14与冠心病合并糖尿病的研究进展

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	黄云, 周丽霞, 马莹莹. 加味杞菊地黄汤治疗糖尿病肾病的疗效及安全性[J]. 承德医学院学报, 2025, 42(6): 486-490.
[2]	张一, 尹丽, 李路广, 李婷婷. 清肺化痰汤对AECOPD患者有效性及免疫功能、炎症因子影响分析[J]. 承德医学院学报, 2025, 42(4): 294-298.
[3]	孟东辉, 李鹏, 陈胜伟. 益气活血通脉汤辅助人工全髋关节置换术对股骨颈骨折患者的影响[J]. 承德医学院学报, 2025, 42(4): 298-302.
[4]	韩思雨, 易梦雅, 李警耀, 张睿, 陈志宏. 胰岛β细胞功能障碍与2型糖尿病相关研究进展[J]. 承德医学院学报, 2025, 42(3): 230-234.
[5]	王玲玲, 姜浩, 朱金伶, 刘瑞林, 朱安军, 耿学丽. NSCLC患者血清AIF-1、IL-6和VEGF水平异常变化及临床意义[J]. 承德医学院学报, 2025, 42(2): 100-106.
[6]	李春博, 刘冰心, 陈梦雅, 阮静. 耳穴压豆中医护理在冠心病心绞痛中的应用[J]. 承德医学院学报, 2025, 42(2): 135-139.
[7]	孔海英, 刘娟娟, 龚连杰. 芍药汤及美沙拉秦治疗溃疡性结肠炎患者的效果[J]. 承德医学院学报, 2025, 42(1): 41-44.
[8]	刘静, 王惠, 王方珍. GDF-15、VEGF、CXCR4与冠心病PCI术后支架再狭窄的关系[J]. 承德医学院学报, 2024, 41(6): 467-471.
[9]	冯滢滢, 朱月月. 血府逐瘀汤对冠心病心绞痛患者的影响[J]. 承德医学院学报, 2024, 41(5): 395-398.
[10]	韩思雨, 李雨欣, 易梦雅, 李警耀, 陈志宏. 丝胶靶向Akt1调控PI3K/Akt信号通路促进STZ致损伤INS-1细胞增殖[J]. 承德医学院学报, 2024, 41(2): 96-100.
[11]	李娟, 徐家新, 王春, 王艳秋, 周路路. 血清Betatrophin对2型糖尿病合并代谢相关脂肪性肝病预测价值的研究[J]. 承德医学院学报, 2023, 40(6): 467-471.
[12]	董锦丽, 柴溶浍, 田立坤. 基于IKAP模式的延续性护理在冠心病患者中的应用效果[J]. 承德医学院学报, 2023, 40(5): 410-414.
[13]	宋立雪, 董雅洁, 卢锴锋, 钱文茹, 巨名飞. 甘油三酯葡萄糖乘积指数对非糖尿病患者冠心病发病的预测价值[J]. 承德医学院学报, 2023, 40(3): 195-198.
[14]	田玉, 周晓蕾, 张博. 清肺化痰解毒汤对痰热壅肺证的影响[J]. 承德医学院学报, 2023, 40(3): 212-215.
[15]	高钰寒, 董志军. 糖尿病视网膜病变炎症相关因子的研究进展[J]. 承德医学院学报, 2023, 40(3): 241-244.